Department of Neurosurgery, Royal North Shore Hospital, St Leonards, Sydney, NSW, 2065, Australia.
Department of Neurosurgery, Westmead Hospital, Sydney, NSW, Australia.
Neurosurg Rev. 2023 Jun 24;46(1):147. doi: 10.1007/s10143-023-02065-6.
Blister aneurysms (BA) are high-risk cerebrovascular lesions accounting for 1% of intracranial aneurysms. The defective vessel wall and broad-based neck make this clinical entity difficult to treat, with high rates of re-rupture and mortality in patients presenting with acute subarachnoid haemorrhage. Blister aneurysms pose substantial challenges for both endovascular and microsurgical management. The objective of this study is to evaluate endovascular and microsurgical outcomes in intracranial blister aneurysm management across two tertiary hospitals. A review of two tertiary hospitals with a systematic imaging database search for term of "blister" in modalities from January 2010 to October 2022 was conducted. Operation reports were screened for the 5-year period since cerebral angiogram reports transitioned to surgical database. Identified reports were screened and reviewed for confirmed diagnosis by consultant neuroradiologist. A total of 21 cases of blister aneurysms managed at respective facilities were included. Sixteen cases (76%) were managed endovascularly. Four cases (19%) were managed surgically-2 with primary clipping, and 2 wrap and clipping. One case was managed conservatively (5%). Clinical outcomes were discharge disposition, aneurysm exclusion and post-operative complications. BAs have challenging considerations with high mortality and morbidity. Endovascular treatment offers a less invasive modality with lower rates of intraoperative rupture and morbidity. Mortality rates and patients discharged home were comparable. Commencement of dual anti-platelet therapy was safe in patients with flow diversion stents despite sub-arachnoid blood volume. Management of blister aneurysms is complex. Endovascular treatment shows promise for acute management but careful collaborative consideration of antithrombotic regime and requirement for further surgery should be considered.
泡状动脉瘤(BA)是一种高风险的脑血管病变,占颅内动脉瘤的 1%。其血管壁缺陷和宽基底颈部使得这种临床实体难以治疗,伴有急性蛛网膜下腔出血的患者再破裂和死亡率较高。泡状动脉瘤给血管内和显微外科治疗都带来了很大的挑战。本研究的目的是评估两家三级医院在颅内泡状动脉瘤管理中的血管内和显微外科治疗结果。对两家三级医院进行了回顾性研究,使用系统的影像学数据库,对 2010 年 1 月至 2022 年 10 月间模态中“泡状”一词进行了搜索。在脑动脉造影报告转入手术数据库的 5 年期间,对手术报告进行了筛选。筛选出的报告由顾问神经放射学家进行确认诊断。共纳入 21 例在各自医院接受治疗的泡状动脉瘤患者。16 例(76%)采用血管内治疗。4 例(19%)采用手术治疗-2 例采用原发性夹闭,2 例采用包裹和夹闭。1 例采用保守治疗(5%)。临床结果为出院情况、动脉瘤排除和术后并发症。BA 具有挑战性,死亡率和发病率都很高。血管内治疗提供了一种侵入性较小的治疗方法,术中破裂和发病率较低。死亡率和出院回家的患者比例相当。尽管蛛网膜下腔血容量增加,但开始双重抗血小板治疗对血流分流支架患者是安全的。泡状动脉瘤的治疗很复杂。血管内治疗对急性管理有希望,但应仔细考虑抗血栓治疗方案和进一步手术的要求。